Venom Immunotherapy: From Proteins to Product to Patient Protection
Authors:
- Martin FeindorMFMartin Feindor
- Matthew D. HeathMHMatthew D. Heath
- Simon J. HewingsSHSimon J. Hewings
- Thalia L. Carreno VelazquezTVThalia L. Carreno Velazquez
- Simon BlankSimon Blank
- Johannes GroschJGJohannes Grosch
- Thilo JakobTJThilo Jakob
- Peter Schmid-GrendelmeierPSPeter Schmid-Grendelmeier
- Ludger KlimekLKLudger Klimek
- David B. K. GoldenDGDavid B. K. Golden
- Murray A. SkinnerMSMurray A. Skinner
- Matthias F. KramerMKMatthias F. Kramer
Open Access
Abstract
In this review, we outline and reflect on the important differences between allergen-specific immunotherapy for inhalant allergies (i.e., aeroallergens) and venom-specific immunotherapy (VIT), with a special focus on Venomil® Bee and Wasp. Venomil® is provided as a freeze-dried extract and a diluent to prepare a solution for injection for the treatment of patients with IgE-mediated allergies to bee and/or wasp venom and for evaluating the degree of sensitivity in a skin test. While the materials that make up the product have not changed, the suppliers of raw materials have changed over the years. Here, we consolidate relevant historical safety and efficacy studies that used products from shared manufacture supply profiles, i.e., products from Bayer or Hollister–Stier. We also consider the characterization and standardization of venom marker allergens, providing insights into manufacturing controls that have produced stable and consistent quality profiles over many years. Quality differences between products and their impacts on treatment outcomes have been a current topic of discussion and further research. Finally, we review the considerations surrounding the choice of depot adjuvant most suitable to augmenting VIT.Keywords
This publication has 67 references indexed in Scilit:
- Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extractsAllergy, 2011
- Outcome survey of insect venom allergic patients with venom immunotherapy in a rural populationJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2008
- Molecular cloning and expression of icarapin, a novel IgE‐binding bee venom proteinFEBS Letters, 2006
- Continuous immunotherapy for hymenoptera venom allergy using six month intervalsAllergologia et Immunopathologia, 2005
- Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparationsAllergy, 2004
- Individual Hymenoptera Venom Compounds Induce Upregulation of the Basophil Activation Marker Ectonucleotide Pyrophosphatase/Phosphodiesterase 3 (CD203c) in Sensitized PatientsInternational Archives of Allergy and Immunology, 2002
- Side‐effects of insect venom immunotherapy:results from an EAACI multicenter studyAllergy, 2000
- Allergens in Hymenoptera venom XXV: The amino acid sequences of antigen 5 molecules and the structural basis of antigenic cross-reactivityJournal of Allergy and Clinical Immunology, 1993
- Rapid Hymenoptera venom immunotherapy: comparative safety of three protocolsClinical & Experimental Allergy, 1993
- Rush venom immunotherapy: a 3‐day programme for hymenoptera sting allergyClinical & Experimental Allergy, 1984